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Do statins delay onset or slow 
progression of Alzheimer’s dementia?
■ Evidence summary
Approximately 4 million people in the
United States suffer with Alzheimer’s 
disease. The prevalence rises with age and
is approximately 47% among those aged
85 years and older.7
Amyloid plaques are thought to be
responsible for clinical changes associated
with Alzheimer’s dementia. Research has
indicated that amyloid precursors may be
more prevalent in a cholesterol-rich envi-
ronment. This led to the theory that treat-
ing hypercholesterolemia may decrease the
prevalence of Alzheimer’s disease.8
The PROSPER trial, which was
designed to test the effect of pravastatin
(Pravachol) on coronary heart disease and
stroke, randomized 5804 study partici-
pants into 1 group assigned to take pravas-
tatin and another group assigned to take
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Statins (coenzyme-A reductase inhibitors) should
not be used with the single intent to delay the
onset or slow the progression of dementia. Large
randomized control trials (RCTs) found that the
administration of a statin had no significant effect
on preventing or slowing all-cause cognitive
decline (strength of recommendation [SOR]: A,
based on large RCTs with narrow confidence 
interval).1,2 Specifically, there is insufficient 
evidence that statins delay the onset or slow the
progression of Alzheimer’s dementia (SOR: B,
based on systematic review with heterogeneity).3
While 3 epidemiologic studies4–6 have found 
a decreased incidence of dementia among those
taking statins, these studies have significant
methodological shortcomings and do not show 
a causal relationship (SOR: C, based on poor-
quality studies). 
E V I D E N C E - B A S E D A N S W E R
We are obligated to protect patients from
potential risks of unnecessary medications
Alzheimer’s disease is a difficult and emotionally
charged topic. Many patients who have watched 
a family member suffer from Alzheimer’s disease
would go to great lengths to delay or prevent
developing Alzheimer’s disease themselves. As a
result of direct drug marketing to consumers, plus
increased lay media coverage of health issues, our
patients are now better informed than ever and
make more direct requests for certain medications
by name. 
Imagine talking with a well-read patient who
has learned from a newspaper article or morning
news show about 1 of the 3 epidemiological 
studies that show decreased incidence of dementia
among statin users. The patient now stands before
you, requesting a prescription for a statin. Though
this patient is otherwise healthy and has a desir-
able cholesterol level, you will still find it difficult
to explain to the patient why you will not write the
prescription. As physicians, we are obligated to
protect our patients from the potential risks of
unnecessary medications. We are also 
obligated to protect our healthcare system from
escalation of already high healthcare costs.
Evidence from rigorous clinical trials is the tool
that can help us provide this protection. 
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placebo. An additional study endpoint was
pravastatin’s effect on cognitive function as
measured by 4 different tests, including the
Mini-Mental Status Exam (MMSE).
Overall cognitive function declined at the
same rate in treatment and placebo
groups. There was no significant difference
between the 2 groups over 3 years using 4
different methods of assessment. In partic-
ular, the MMSE scores differed by only
0.06 points (95% confidence interval [CI],
0.04–0.16; P=.26). 
The largest RCT of a statin agent, the
Heart Protection Study, enrolled more
than 20,000 people and randomized them
to simvastatin (Zocor) or placebo. After a
median of 5 years of follow-up, there was
no difference in cognitive scores or the 
rate of diagnosis of dementia between the
2 groups.2
A systematic review concluded that
no good evidence recommended statins
for reducing the risk of Alzheimer’s
dementia.3 Notably, the review did find a
body of inconclusive evidence that lower-
ing serum cholesterol may retard disease
pathogenesis. An observational study of
56,790 charts included in the computer
databases of 3 hospitals found that the
prevalence of probable Alzheimer’s
dementia in the cohort taking statins was
60% to 73% (P<.001) lower than in the
total patient population or in patients
taking antihypertensive or cardiovascular
medications.4
Also included in the review was a nest-
ed case-control study of 1364 patients that
found an adjusted relative risk for demen-
tia of 0.29 (95% CI, 0.013–0.063; P=.002)
among those taking statins.5 This study did
not distinguish between Alzheimer’s
dementia and other forms of dementia.
These studies do not demonstrate a 
causal relationship between statins and
Alzheimer’s dementia. 
The best way to determine if there is a
true effect of statins on Alzheimer’s demen-
tia is to conduct a clinical trial. Two 
ongoing clinical trials are designed specifi-
cally to determine if the use of statins delay
the onset or slow the progression of
Alzheimer’s dementia.9,10 To date, these 
trials have not published interim findings. 
Recommendations from others
No organization has issued recommenda-
tions for the use of statins to delay the
onset or slow the progression of
Alzheimer’s dementia.
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